US investor Odyssey Therapeutics acquires majority stake in Britain’s quantum drug discovery start-up Rahko

By IQT News posted 13 Dec 2021

(Telegraph) London-based Rahko, which was developing software designed to utilise quantum computers for drug discovery, has been swooped upon by US-based Odyssey Therapeutics.
Odyssey, which is based in Boston, confirmed this week that it had raised $218m in venture capital funding to back new drugs and drug discovery technologies. It has acquired a majority stake in Rahko, which was founded in 2018 by computer science graduates at UCL. The start-up previously secured funding from Balderton Capital in 2019. Click here to read Odyssey’s news release of its $218M funding
Rahko’s website states that it is “solving drug discovery with quantum machine learning”, developing a drug discovery service called Hyrax that applies drug discovery algorithms to quantum computers. It has around a dozen staff, according to LinkedIn. One technology investor said Rahko had struggled to raise additional funds. Rahko and Odyssey did not respond to requests for comment.

Subscribe to Our Email Newsletter

Stay up-to-date on all the latest news from the Quantum Technology industry and receive information and offers from third party vendors.

0